Helix (HLXA) Shareholders Approve Moonlake Immunotherapeutics Deal
Helix Acquisition Corp. (NASDAQ:HLXA) announced this afternoon that its shareholders have voted to approve its combination with biotech firm Moonlake.
At today’s special meeting, a total of 12,048,085, or approximately 81%, of Helix’s issued and outstanding ordinary shares were present. ...READ MORE
